Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor pathway in the liver, which is a key regulatory mechanism common to a spectrum of cardio-metabolic and fatty liver diseases with high unmet medical need. The Company has advanced its lead candidate, MGL-3196, a first-in-class, orally administered, small-molecule, liver-directed, thyroid hormone receptor (THR) β-selective agonist, through Phase 2 clinical trials in non-alcoholic steatohepatitis (NASH) and heterozygous familial hypercholesterolemia (HeFH). Primary and key secondary endpoints were achieved including reduction of liver fat on a sensitive non-invasive imaging test, lowering of multiple atherogenic lipids including LDL-cholesterol and triglycerides, and resolution of NASH on liver biopsy. Based on evidence of broad activity and a favorable safety profile, Madrigal plans to initiate a Phase 3 clinical program in NASH, and a second Phase 3 clinical program in a broader segment of patients with dyslipidemia, including potentially patients with earlier stages of fatty liver disease who, like the later stage NASH patients, are at high risk of cardiovascular disease.
Phase 2 Results for Madrigal’s MGL-3196 in Non-Alcoholic Steatohepatitis (NASH) Presented during Presidential Plenary Clinical Session of The Liver Meeting® 2018
Pursuing novel therapeutics for
CARDIO-METABOLIC AND FATTY-LIVER DISEASES
Advancing MGL-3196 as
THR-β SELECTIVE AGONIST FOR NASH